You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 4,978,332

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,978,332

Title:	Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
Abstract:	A pharmaceutical composition and method of treating cellular disorders involving abnormal solid cellular growths which comprises administering a pharmaceutical composition containing cytotoxic agents in combination with a vasoconstrictive drug. Enhanced effectiveness of the composition is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Agents may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.
Inventor(s):	Luck; Edward E. (Menlo Park, CA), Brown; Dennis M. (Menlo Park, CA)
Assignee:	Matrix Pharmaceutical, Inc. (Menlo Park, CA)
Application Number:	07/101,599
Patent Claims:	1. A method for treating a neoplastic lesion or surrounding tissue which comprises: applying at the site of said length a composition consisting essentially of a uniformly dispersed vasconstrictive drug and at least one uniformly dispersed cytotoxic drug in a non-proteinaceous aqueous medium; whereby said drug is retained in the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction. 2. A method according to claim 1, wherein said vasoconstrictive drug is at least one of the following: epinephrine, norepinephrine, the catecholamines, epinephrine isoproterenol, dopamine, ephedrine, phenylephrine, amphetamine, metraminol, methoxamine, ergot alkaloids, ergonovine, methylergonavine, methysergide, ergotamine, an angiotensin, and a prostaglandin: said vasoconstrictive drug present in a therapeutically effective amount. 3. A method according to claim 1, wherein said cytotoxic drug is at least one of the following: an alkylating agent, enzyme inhibitor, lytic agent, DNA synthesis inhibitor, membrane permeability modifier, DNA intercalator, or antimetabolite. 4. A method according to claim 1, wherein said cytotoxic drug is at least one of the following: cisplatin, doxorubicin hydrochloride, bleomycin sulfate, fluorouracil, vincristine sulfate, vinblastine sulfate, chlorambucil, melphalan, busulfan, carmustine, lomustine, streptozotocin, thiotepa, dacarbazine, methotrexate, cytarabine, azaribine, mercaptopurine, thioguanine, actinomycin D, plicamycin, mitomycin-C, asparaginase, procarbazine hydrochloride, prednisone, prednisi iamcinolone, testosterone, estrogen, insulin, BUdR nitrosourea, hydroxyurea. 5. A method according to claim 1, wherein said composition in addition consists of an agent affecting tissue architecture and present in a therapeutically effective amount. 6. A method according to claim 5, wherein said agent affecting tissue architecture is at least one of papain, chymopapain, trypsin, amylase, collagenase and chymotrypsin. 7. A method according to claim 1, wherein said composition in addition consists of an agent affecting cellular permeability and present in a therapeutically effective amount. 8. A method according to claim 7, wherein said agent affecting cellular permeability is at least one of detergents, amphotericin B and dimethylsulfoxide. 9. A method according to claim 1, wherein an affecting cytotoxic activity which is at least one of radionuclides technicium or iridium, misonidazole and cytokines is present in said medium in a therapeutically effective amount. 10. A method according to claim 1, comprising the additional step of treating said lesion site with radiation or heat applied in a therapeutically effective amount. 11. A pharmaceutical composition consisting essentially of a vasoconstrictive drug, a cytotoxic drug and a protein-free aqueous pharmacologically acceptable vehicle. 12. A pharmaceutical composition according to claim 11, wherein said vasoconstrictive drug is at least one of the following: epinephrine, norepinephrine, the catecholamines, epinephrine isoproterenol, dopamine, ephedrine and other phenylisopropylamines, phenylephrine, amphetamine, metraminol, methoxamine, ergot alkaloids, ergonovine, methylergonavine, methysergide, ergotamine, the angiotensins and the prostaglandins. 13. A pharmaceutical composition according to claim 11, wherein said cytotoxic drug is at least one of the following: an alkylating agent, enzyme inhibitor, lytic agent, DNA synthesis inhibitor, DNA intercalator, or antimetabolite. 14. A pharmaceutical composition according to claim 11, wherein said cytotoxic drug is at least one of the following: cisplatin, doxorubicin hydrochloride, bleomycin sulfate, fluorouracil, vincristine sulfate, vinblastine sulfate, chlorambucil, melphalan, busulfan carmustine, lomustine, streptozotocin, thiotepa, dacarbazine, methotrexate, cytarabine, azaribine, mercaptopurine, thioguanine, actinomycin D, plicamycin, mitomycin-C, asparaginase, procarbazine hydrochloride, prednisone, prednisilone, triamcinolone, testosterone, estrogen, insulin, BUdR, nitrosourea, carmustine, lomustine, and hydroxyurea. 15. A pharmaceutical composition according to claim 11, in addition consisting of an agent affecting tissue architecture and present in a therapeutically effective amount. 16. A pharmaceutical composition according to claim 15, wherein said agent affecting tissue architecture is at least one of papain, chymopapain, trypsin, amylase, collagenase and chymotrypsin. 17. A pharmaceutical composition according to claim 11, in addition consisting of an agent affecting cellular permeability and present in a therapeutically effective amount. 18. A pharmaceutical composition according to claim 17, wherein said agent affecting cellular permeability is at least one of detergents, amphotericin B and dimethylsulfoxide. 19. A pharmaceutical composition according to claim 11, in addition consisting of an agent affecting said cytotoxic activity and present in a therapeutically effective amount. 20. A pharmaceutical composition according to claim 19, wherein said agent affecting cytotoxic activity is at least one of radionuclides technicium or iridium, nitroimidazoles, and cytokines.

Details for Patent 4,978,332

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	11/10/1982	⤷ Try a Trial	2039-03-29
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	08/21/1984	⤷ Try a Trial	2039-03-29
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2039-03-29
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.